tbuckley/cabot-search huggingface dataset:
Dysregulated Autophagy and Lysosome Function Are Linked to Exosome Production by Micro‐RNA 155 in Alcoholic Liver Disease
Authors: Mrigya Babuta, Istvan Furi, Shashi Bala, Terence N. Bukong, Patrick Lowe, Donna Catalano, Charles Calenda, Karen Kodys, Gyongyi Szabo
Journal: Hepatology (2019)

Cellular homeostais, that is normally maintained through autophagy, is disrupted in alcoholic liver disease (ALD). Because autophagy and exosome biogenesis share common elements, we hypothesized that increased exosome production in ALD may be linked to disruption of autophagic function. We found impaired autophagy both in ALD and alcoholic hepatitis (AH) mouse models and human livers with ALD as indicated by increased hepatic p62 and LC3‐II levels. Alcohol reduced autophagy flux in vivo in chloroquine‐treated mice as well as in vitro in hepatocytes and macrophages treated with bafilomycin A. Our results revealed that alcohol targets multiple steps in the autophagy pathway. Alcohol‐related decrease in mechanistic target of rapamycin (mTOR) and Ras homolog enriched in brain (Rheb), that initiate autophagy, correlated with increased Beclin1 and autophagy‐related protein 7 (Atg7), proteins involved in phagophore‐autophagosome formation, in ALD. We found that alcohol disrupted autophagy function at the lysosomal level through decreased lysosomal‐associated membrane protein 1 (LAMP1) and lysosomal‐associated membrane protein 2 (LAMP2) in livers with ALD. We identified that micro‐RNA 155 (miR‐155), that is increased by alcohol, targets mTOR, Rheb, LAMP1, and LAMP2 in the authophagy pathway. Consistent with this, miR‐155‐deficient mice were protected from alcohol‐induced disruption of autophagy and showed attenuated exosome production. Mechanistically, down‐regulation of LAMP1 or LAMP2 increased exosome release in hepatocytes and macrophages in the presence and absence of alcohol. These results suggested that the alcohol‐induced increase in exosome production was linked to disruption of autophagy and impaired autophagosome and lysosome function. Conclusion: Alcohol affects multiple genes in the autophagy pathway and impairs autophagic flux at the lysosome level in ALD. Inhibition of LAMP1 and LAMP2 promotes exosome release in ALD. We identified miR‐155 as a mediator of alcohol‐related regulation of autophagy and exosome production in hepatocytes and macrophages.
Immunotherapeutic strategies for cutaneous squamous cell carcinoma prevention in xeroderma pigmentosum
Authors: A.H. Ameri, M.J. Mooradian, K.S. Emerick, J.C. Park, L.J. Wirth, M.M. Asgari, H. Tsao, D. Lawrence, R.J. Sullivan, S. Demehri
Journal: British Journal of Dermatology (2019)
Electrocardiographic Changes After Overdose of Epinephrine in a Patient With Anaphylaxis
Authors: Chunyan Jiang, Hongwei Li
Journal: JAMA Internal Medicine (2019)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Internal Medicine HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Internal Medicine journal
PER-ORAL ENDOSCOPIC PYLOROMYOTOMY (G-POEM) FOR THE TREATMENT OF REFRACTORY GASTROPARESIS
Authors: R Hustak, Z Rabekova, Z Vackova, M Kollar, J Krajciova, J Spicak, J Martinek
Journal: Endoscopy (2019)

G-POEM is a new promising method for the treatment of refractory gastroparesis (GP). So far, small studies have been published suggesting its short-term efficacy and low incidence of periprocedural complications, but more data is necessary to assess the real role of G-POEM in clinical practice. The aim of our pilot study was to assess long-term (more than 12 months) clinical effectiveness, safety and technical aspects of G-POEM in consecutive patients with refractory GP.
Thomas Burnett Hogarth
Authors: Patrick J Bradley
Journal: BMJ (2019)

Thomas Burnett Hogarth (“Tom”) joined the Royal Army Medical Corps (1942-48) and was attached as a regimental surgeon to the 1st/10th Gurkha Rifles, Kluang, Malaysia. He described this period as the “best years of my life.” He was educated at Epsom College (1936-1939). He first came to …
Abstract B13: The impact of combined CDK9 inhibition and TRAIL treatment on NSCLC
Authors: Itziar Areso Zubiaur, Antonella Montinaro, Silvia von Karstedt, Johannes Lemke, Torsten Hartwig, Lucia Taraborelli, Silvia Surinova, Mona A. El-Bahrawy, Henning Walczak
Journal: Clinical Cancer Research (2018)

Abstract Tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) has been shown to specifically kill cancer cells in vivo. On the basis of this, TRAIL-receptor (TRAIL-R) agonists were devised for clinical use. However, to date, TRAIL-R agonists have only shown limited therapeutic benefit in clinical trials. This can most likely be attributed to the fact that most primary human cancers are TRAIL resistant. It is therefore important to identify potent and cancer-selective TRAIL-sensitizers that overcome TRAIL resistance. Recently, the combination of CDK9 inhibition with TRAIL was found to effectively induce apoptosis in a panel of TRAIL-resistant non-small cell lung cancer (NSCLC) cell lines. Furthermore, tumors from NSCLC patients show high expression levels of CDK9, providing a rationale for targeting CDK9 in lung cancer. Here, we evaluate how effective the new TRAIL/CDK9 inhibition combination therapy is in treating lung cancer in an autochthonous mouse model (the KrasG12D/p53R172H) that closely recapitulates the human disease. We found that this combination was highly effective in vivo and led to a significant tumor regression and prolonged the survival of these mice. Our most recent results regarding these effects will be presented. Citation Format: Itziar Areso Zubiaur, Antonella Montinaro, Silvia von Karstedt, Johannes Lemke, Torsten Hartwig, Lucia Taraborelli, Silvia Surinova, Mona A. El-Bahrawy, Henning Walczak. The impact of combined CDK9 inhibition and TRAIL treatment on NSCLC [abstract]. In: Proceedings of the Fifth AACR-IASLC International Joint Conference: Lung Cancer Translational Science from the Bench to the Clinic; Jan 8-11, 2018; San Diego, CA. Philadelphia (PA): AACR; Clin Cancer Res 2018;24(17_Suppl):Abstract nr B13.
Sténose pyloro-duodenale d'origine ulcéreuse: Caractéristiques épidémiologiques, cliniques et résultats du traitement endoscopique
Authors: M Ayari, S Ayadi, E Bel Hadj Mabrouk, Y Zaimi, K El Jeri, Y Said, L Mouelhi, R Debbeche
Journal: Endoscopy (2019)

L'usage de plus en plus répondu des inhibiteurs des pompes à protons (IPP) a considérablement réduit la fréquence de la sténose bulbaire (SB) compliquant la pathologie ulcéreuse gastro-duodénale. Autrefois systématiquement chirurgicale, la thérapeutique repose actuellement sur le traitement médical et endoscopique. L'objectif de notre étude est de d'étudier caractéristiques cliniques et paracliniques des sténoses bulbaires et d'évaluer les résultats des dilatations endoscopiques dans le traitement des SB.
Social media companies will be overseen by independent regulator, pledges government
Authors: Elisabeth Mahase
Journal: BMJ (2019)

The government has pledged to develop a regulatory framework to make clear the responsibilities that social media companies have to their users.1

It said that the framework would establish a duty of care towards all UK users and would be overseen by a new independent regulator with statutory powers.

It made the pledge in response to a report by the House of Commons Science and Technology Committee on the impact of social media on young people’s health, published in January.2 This called for a regulator to be appointed by the …
John Lennard-Jones 1927–2019: physician and gastroenterologist
Authors: Michael Farthing
Journal: Gut (2019)

Professor John Lennard-Jones, affectionately known by his colleagues as ‘LJ’, was an exceptional man; a caring and astute physician, a gentle but inspirational teacher and a prodigious clinical researcher. His clinical judgements were always well considered and invariably correct. He inspired supreme confidence in his patients and was an extraordinary role model for professional colleagues whose lives he touched.

Born in 1927 he was the son of John Edward Lennard-Jones, a professor of theoretical chemistry at Cambridge and Kathleen (nee Lennard); the binomial was created by his father on their marriage to recognise the loss of Kathleen’s two brothers in WW1 and to continue the name. He attended King’s College Choir School, as a non-chorister, and Gresham’s School in Norfolk where latterly he studied mathematics, physics and chemistry. During his childhood and adolescence his main interest was the natural world; the birds and wild flowers that surrounded his semirural home in Cambridge and a diverse assembly of domestic animals for which he cared including geese, hens, ducks, rabbits, a ferret (Joey) and a goat. During postwar rationing he supplemented the family diet with his home-grown vegetables. He was destined to become a farmer but in 1946 at the age 19 he was called up to do National Service and was posted as an orderly to the Burns Unit, Birmingham. The human tragedies that he witnessed there changed his direction and he returned to Corpus Christi College, Cambridge in 1948 aged 21 to study medicine. He had not wasted his time at the Burns Unit and in the following year he published two papers, one in the Lancet on the value of systemic penicillin …
Abstract 16787: Platelet Depletion Reduces Bioresorbable Vascular Graft Calcification in a Mouse Aortic Model
Authors: Hideki Miyachi, Shuhei Tara, Satoru Otsuru, Shinka Miyamoto, Tai Yi, Joseph Drews, Hidetaka Nakayama, Toshihiro Shoji, Tadahisa Sugiura, Christopher K Breuer, Toshiharu Shinoka
Journal: Circulation (2017)

Introduction: Ectopic calcification remains a major obstacle for arterial bioresorbable vascular grafts (BVGs). Platelets are important to hemostatic, inflammatory, and atherosclerotic functions. H...
A prospective, multicenter, international randomized trial comparing four reperfusion strategies in acute myocardial infarction: Principal report of the Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC) trial
Authors: GW Stone, CL Grines, DA Cox, E Garcia, JE Tcheng, T Stuckey, J Carroll, G Guagliumi, B Rutherford, G Johnson, M Effron, P Esente, AJ Lansky, J Griffin
Journal: Journal of the American College of Cardiology (2001)
CD146 suppresses breast tumor via its novel downstream signaling pathway, Latexin/Akt/NFκB
Authors: A. Ouhtit, A. Fernando
Journal: Annals of Oncology (2019)

Background: CD146 or Mel-CAM, a member of the immunoglobulin-like CAM family, is activated through a dimerization of its ligand, leading to a cascade of signal transduction events. While CD146 is a promoter of melanoma and prostate cancer, its role in BC remains nascent and controversial. However, we have recently reported that CD146, a negative transcriptional target of CD44-HA downstream signaling, suppresses breast tumor cell invasion; this has prompted us to generate the hypothesis that CD146 acts as a tumor suppressor in BC via its downstream transcriptional targets. Methods: To test this hypothesis, we developed both in vitro and in vivo tetracycline (tet On)-inducible system of CD146 using MDA-MB-231 founder BC cell line. Our results demonstrated that induction of CD146 suppressed BC cell migration and invasion in vitro as well as tumor growth and progression in mouse breast xenograft model. Microarray gene expression profiling revealed latexin (LXN: a variant of Tissue Inhibitor of Metalloproteinases) as a novel potential CD146-downstream signaling transcriptional target, which was validated using various in vitro approaches. Results: To further validate our finding in vivo, immunohistochemical analysis of breast tumor tissues from both human and mouse (tet-inducible system) breast tissues showed that, while the expression of both CD146 and LXN were highly expressed in the early stages of BC (normal and benign tissues), it was lost in advanced stages (malignant and metastatic tissues). Pharmacological approach combined with luciferase assay revealed that NFκB activation via Akt pathway couples CD146 to the transcription of LXN in BC CD146inducible cells. Conclusions: The present study discovers the main molecular players of a novel signaling pathway, CD146/LXN/Akt/N-κB, by which CD146 acts as a suppressor of BC progression. Legal entity responsible for the study: Allal Ouhtit. Funding: Qatar University. Disclosure: All authors have declared no conflicts of interest.
DIAGNOSIS OF BARRETT'S ESOPHAGUS IN UNIVERSITY HOSPITAL CENTRE ZAGREB BETWEEN 2012 AND 2017
Authors: L Franolić, P Markoš, I Škrlec, H Iveković, M Kalauz, B Bilić, N Rustemović
Journal: Endoscopy (2019)

To evaluate basic epidemiology situation and demographic data of patients diagnosed with Barrett's esophagus in University Hospital Centre Zagreb between January 2012 and December 2017.
INTRAMURAL COLONIC HEMATOMA: A RARE COMPLICATION OF ENDOSCOPIC SUBMUCOSAL DISSECTION
Authors: P Soriani, T Gabbani, S Deiana, V Giorgio Mirante, M Manno
Journal: Endoscopy (2019)

Intramural colonic hematoma represents a rare complication, following blunt trauma, therapeutic intervention or accompanying diseases with bleeding diathesis.
HDAC3 Deficiency Promotes Liver Cancer through a Defect in H3K9ac/H3K9me3 Transition
Authors: Hongjie Ji, Yongjie Zhou, Xiang Zhuang, Yongjie Zhu, Zhenru Wu, Yannrong Lu, Shengfu Li, Yong Zeng, Qing R. Lu, Yanying Huo, Yujun Shi, Hong Bu
Journal: Cancer Research (2019)

Abstract DNA damage triggers diverse cancers, particularly hepatocellular carcinoma (HCC), but the intrinsic link between DNA damage and tumorigenesis remains unclear. Because of its role as an epigenetic and transcriptional regulator, histone deacetylase 3 (HDAC3) is essential for DNA damage control and is often aberrantly expressed in human HCC. In this study, we used individual class I HDAC member–deficient mice to demonstrate that K9 in histone H3 (H3K9), which is the critical site for the assembly of DNA damage response complexes, is exclusively targeted by HDAC3. Ablation of HDAC3 disrupted the deacetylation and consequent trimethylation of H3K9 (H3K9me3), the first step in double-strand break repair, and led to the accumulation of damaged DNA. Simultaneously, hyperacetylated H3K9 (H3K9ac) served as a transcriptional activator and enhanced multiple signaling pathways to promote tumorigenesis. Together, these results show that HDAC3 targets the H3K9ac/H3K9me3 transition to serve as a critical regulator that controls both DNA damage repair and the transcription of many tumor-related genes. Moreover, these findings provide novel insights into the link between DNA damage and transcriptional reprogramming in tumorigenesis. Significance: These findings show that HDAC3 exclusively regulates H3K9ac in response to DNA damage, and loss of HDAC3 activity shifts the balance from DNA damage control to protumorigenic transcriptional activity.
Machine Learning at the Clinical Bedside—The Ghost in the Machine
Authors: Joseph J. Zorc, James M. Chamberlain, Lalit Bajaj
Journal: JAMA Pediatrics (2019)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Pediatrics HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Pediatrics journal
Genomic epidemiology of Neisseria meningitidis serogroup W in Switzerland between 2010 and 2016
Authors: Stefano Leo, Vladimir Lazarevic, Myriam Girard, Gisela C. Getaz-Jimenez Velasco, Luke Anson, Nadia Gaïa, Gesuele Renzi, Abdessalam Cherkaoui, Rita Born, Sabine Basler, Jacques Schrenzel
Journal: Journal of Infection (2019)
Post-discharge Bleeding and Thienopyridine Discontinuation among AMI Patients Treated with PCI: Insights from the TRANSLATE-ACS Study
Authors: Tracy Y. Wang, Emily Honeycutt, Timothy D. Henry, Mark B. Effron, John C. Messenger, David J. Cohen, Daniel B. Mark, Gregg W. Stone, Mandeep Singh, Maurice Rozek, Gregg C. Fonarow, Eric D. Peterson
Journal: Journal of the American College of Cardiology (2011)
Cerebral Perfusion Goals During Cardiopulmonary Bypass—The Goldilocks Effect
Authors: Laura Seese, Arman Kilic, Danny Chu
Journal: JAMA Surgery (2019)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Surgery HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Surgery journal
HISTOLOGICAL PROFILE OF HELICOBACTER PYLORI-INDUCED CHRONIC GASTRITIS: ABOUT 227 CASES
Authors: M Kadi, M Eljihad, M Tahiri Joutei-Hassani, W Badre, W Hliwa, F Haddad, A Bellabah
Journal: Endoscopy (2019)

The aim of our work is to define the different histological aspects of gastritis associated with HP infection.
Asking the right question: implementation research to accelerate national non-communicable disease responses
Authors: David H Peters, Michael A Peters, Kremlin Wickramasinghe, Patrick L Osewe, Patricia M Davidson
Journal: BMJ (2019)

Non-communicable disease programmes can be strengthened by systematically identifying implementation challenges and translating them into questions that can be answered through appropriate research, say <b>David H Peters and colleagues</b>
The first-in-human study of the pan-PIM kinase inhibitor PIM447 in patients with relapsed and/or refractory multiple myeloma
Authors: Marc S. Raab, Sheeba K. Thomas, Enrique M. Ocio, Andreas Guenther, Yeow-Tee Goh, Moshe Talpaz, Nicolas Hohmann, Sylvia Zhao, Fang Xiang, Carl Simon, K. Gary Vanasse, Shaji K. Kumar
Journal: Leukemia (2019)
Linkage Groups within Thiol–Ene Photoclickable PEG Hydrogels Control In Vivo Stability
Authors: Michael D. Hunckler, Juan D. Medina, Maria M. Coronel, Jessica D. Weaver, Cherie L. Stabler, Andrés J. García
Journal: Advanced Healthcare Materials (2019)

Abstract Thiol–norbornene (thiol–ene) photoclickable poly(ethylene glycol) (PEG) hydrogels are a versatile biomaterial for cell encapsulation, drug delivery, and regenerative medicine. Numerous in vitro studies with these 4‐arm ester‐linked PEG‐norbornene (PEG‐4eNB) hydrogels demonstrate robust cytocompatibility and ability to retain long‐term integrity with nondegradable crosslinkers. However, when transplanted in vivo into the subcutaneous or intraperitoneal space, these PEG‐4eNB hydrogels with nondegradable crosslinkers rapidly degrade within 24 h. This characteristic limits the usefulness of PEG‐4eNB hydrogels in biomedical applications. Replacing the ester linkage with an amide linkage (PEG‐4aNB) mitigates this rapid in vivo degradation, and the PEG‐4aNB hydrogels maintain long‐term in vivo stability for months. Furthermore, when compared to PEG‐4eNB, the PEG‐4aNB hydrogels demonstrate equivalent mechanical properties, crosslinking kinetics, and high cytocompatibility with rat islets and human mesenchymal stem cells. Thus, the PEG‐4aNB hydrogels may be a suitable replacement platform without necessitating critical design changes or sacrificing key properties relevant to the well‐established PEG‐4eNB hydrogels.
Mucosectomie anti-reflux (ARMS) dans le traitement du reflux gastro-oesophagien réfractaire aux IPP: Etude pilote évaluant la faisabilité et données préliminaires d'éfficacité
Authors: JM Gonzalez, JP Le Mouel, P Basile, V Vitton, M Barthet
Journal: Endoscopy (2019)

Il n'a à ce jour pas de traitement endoscopique validé du reflux gastro oesophagien (RGO) validé malgré les multiples techniques développées et évaluées, qui manquent de faisabilité et restent onéreuses. La mucosectomie oesophagienne est une technique codifiée de référence, dont une application pourrait être le traitement du reflux de par la rétraction qu'elle entraine lors de la cicatrisation si elle est réalisée sur la jonction oeso-gastrique (1, 2). C'est pourquoi nous proposons cette étude pilote évaluant sa faisabilité chez des patients avec RGO réfractaires.
SIX YEARS OF SINGLE CENTER EXPERIENCE WITH PERORAL ENDOSCOPIC MYOTOMY (POEM)
Authors: Z Rabekova, Z Vackova, T Hucl, P Stirand, J Spicak, E Kieslichova, R Janousek, J Martinek
Journal: Endoscopy (2019)

POEM has proved excellent mid-term efficacy even when compared with other standard methods for treatment of achalasia, but the long-term durability still needs to be confirmed. Nevertheless, the high risk of post-POEM reflux tempers the enthusiasm. The aim of our study was to assess the long-term clinical outcome of POEM and a thorough analysis of post-POEM reflux.